

Randomised, double-blind, placebo-controlled trial. Patients with CD undergoing a surgical resection of <1metre of bowel resection removing all macroscopic lesions were randomised to receive 2 packets per day of lyophilised *Lactobacillus johnsonii* LA1 (LA1) ( $2 \times 10^9$  cfu) of placebo for six months

Primary endpoint: Endoscopic recurrence at six months (Rutgeerts >1)


Results: N=98

- Endoscopic recurrence 49% LA1 vs 64% placebo,  $p=0.15$
- Endoscopic score distribution did not differ between LA1 and placebo.
- Clinical recurrence did not differ between groups.

Conclusion:

*L johnsonii* LA1 ( $4 \times 10^9$  cfu/day) did not have a sufficient effect, if any, to prevent endoscopic recurrence of Crohn's disease

**Ineffectiveness of *Lactobacillus johnsonii* LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial**



**Figure 2** Grade of endoscopic lesions (G0–4) at follow up (six months or earlier in case of clinical relapse) in patients receiving *Lactobacillus johnsonii* LA1 or placebo after surgery for Crohn's disease.

